Navigation Links
Cardinal Health Reports Third-Quarter Results
Date:5/3/2012

DUBLIN, Ohio, May 3, 2012 /PRNewswire/ -- Cardinal Health today reported a 3 percent increase in fiscal 2012 third-quarter revenue to $26.9 billion and a 6 percent increase in non-GAAP operating earnings to $524 million. The company also reported a 16 percent increase in non-GAAP diluted earnings per share (EPS) from continuing operations to $0.94.

"We are pleased to report another solid quarter of revenue growth for both of our business segments, as well as continued strong growth in earnings per share," said George Barrett, chairman and chief executive officer of Cardinal Health. "Our Pharmaceutical segment continued its robust profit performance. Our Medical segment fundamentals showed continued momentum, but as anticipated, profit was negatively impacted by the cost of commodity inputs. However, we see the year-over-year impact of this dynamic subsiding in the fourth quarter of fiscal 2012 and into fiscal 2013."

The company raised the lower end of its guidance resulting in a revised range of $3.15 to $3.20 for fiscal 2012 non-GAAP diluted earnings per share from continuing operations.

Q3 FY12 SUMMARYQ3 FY12Q3 FY11Y/YRevenue

$26.9 billion

$26.1 billion

3% 

Operating Earnings

 

$527 million

 

$447 million

 

18%Non-GAAP Operating Earnings

 

$524 million

 

$493 million

 

6%Earnings from Continuing Operations

 

$332 million

 

$250 million

 

33%Non-GAAP Earnings from Continuing Operations

 

$327 million

 

$286 million

 

14%Diluted EPS from Continuing Operations

 

$0.95

 

$0.71

 

34%Non-GAAP Diluted EPS from Continuing Operations

 

$0.94

 

$0.81

 

16%A reduction in the fair value of the P4 Healthcare acquisition earn-out liability positively impacted third-quarter fiscal 2012 GAAP operating earnings by $55 million and GAAP diluted EPS from continuing operations by $0.10 per share. Third-quarter fiscal 2012 GAAP and Non-GAAP diluted EPS from continuing operations benefited from a lower tax rate than the prior year's higher-than-usual tax rate.

SEGMENT RESULTSPharmaceutical segmentRevenue for the Pharmaceutical segment increased 3 percent to $24.5 billion, driven by growth from existing customers. Segment profit increased 9 percent to $446 million, due to the strong performance of generic programs including the impact of new and recently launched items.Q3 FY12Q3 FY11Y/YRevenue

$24.5 billion

$23.8 billion

3%Segment Profit

$446 million

$411 million

9%Medical segmentRevenue for the Medical segment increased 8 percent to $2.4 billion, driven by growth from existing customers, including strong sales of preferred products. Segment profit declined 17 percent to $89 million, due to the anticipated negative impact of commodity price increases and increased information system expenses, primarily related to the launch of the company's Medical Business Transformation. The decline was partially offset by the positive margin impact of higher preferred products volume. Q3 FY12Q3 FY11Y/YRevenue

$2.4 billion

$2.2 billion

8%Segment Profit

$89 million

$108 million

(17)%ADDITIONAL THIRD-QUARTER AND RECENT HIGHLIGHTS

  • Appointment of Donald M. Casey, Jr. as CEO of company's Medical segment
  • Completion of acquisition of Futuremed Healthcare Products Corp., a distributor of medical disposables and specialized equipment to the long-term care channel in Canada
  • Introduction of the Smart-Seal™ surgical mask, a new line of standard diagnostic procedure trays, and the industry's only half-folded format surgical glove packaging
  • Recognized as one of 2012 top 10 best companies for leaders by "Chief Executive" magazine
  • Named one of the "Top 50 Companies for Executive Women" by the National Association for Female Executives
  • CONFERENCE CALLThe company has scheduled a webcast and conference call for May 3 at 8:30 a.m. Eastern to discuss third-quarter results. To access the call and corresponding slide presentation, go to the Investors page at cardinalhealth.com. Participants accessing the presentation through the website will be asked to register and can do so prior to the call on the Investors page. Participants can also dial 224-357-2209 directly; no passcode or registration will be required. 

    Presentation slides and an audio replay will be archived on the website after the conclusion of the meeting. The audio replay will also be available until June 4 by dialing either 855-859-2056 or 404-537-3406.

    UPCOMING WEBCASTED EVENTS

  • 2012 Deutsche Bank 37th Annual Health Care Conference on May 7 at 9:20 a.m. Eastern in Boston
  • Bank of America Merrill Lynch 2012 Health Care Conference on May 15 at 8:40 a.m. Pacific in Las Vegas
  • Goldman Sachs 33rd Annual Global Healthcare Conference on June 5 at 8:40 a.m. Pacific in Rancho Palos Verdes, Calif.
  • William Blair 32nd Annual Growth Stock Conference on June 14 at 8 a.m. Central in Chicago
  • At these events, Cardinal Health executives will discuss the company's diverse products and services, company performance and strategies for continued growth. To access more details and live webcasts of these events, go to the Investors page at cardinalhealth.com.

    About Cardinal Health
    Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is a $103 billion health care services company that improves the cost-effectiveness of health care. As the business behind health care, Cardinal Health helps pharmacies, hospitals, ambulatory surgery centers and physician offices focus on patient care while reducing costs, enhancing efficiency and improving quality. Cardinal Health is an essential link in the health care supply chain, providing pharmaceuticals and medical products to more than 60,000 locations each day. The company is also a leading manufacturer of medical and surgical products, including gloves, surgical apparel and fluid management products. In addition, the company supports the growing diagnostic industry by supplying medical products to clinical laboratories and operating the nation's largest network of radiopharmacies that dispense products to aid in the early diagnosis and treatment of disease. Ranked #19 on the Fortune 500, Cardinal Health employs more than 30,000 people worldwide. More information about the company may be found at cardinalhealth.com.

    (1) See the attached tables for definitions of the non-GAAP financial measures presented in this news release and reconciliations of the differences between the non-GAAP financial measures and their most directly comparable GAAP financial measures.

    Cardinal Health uses its website as a channel of distribution for material company information. Important information, including news releases, analyst presentations and financial information regarding Cardinal Health is routinely posted and accessible on the Investors page at cardinalhealth.com.

    Cautions Concerning Forward-Looking Statements This news release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include uncertainties due to government health care reform including federal health care reform legislation; competitive pressures in Cardinal Health's various lines of business; the loss of one or more key customer or supplier relationships or changes to the terms of those relationships; the timing of generic and branded pharmaceutical introductions and the frequency or rate of pharmaceutical price appreciation or deflation; changes in the distribution patterns or reimbursement rates for health care products and services; the effects of any investigation or action by any regulatory authority, including the Drug Enforcement Administration's suspension of the company's Lakeland, Fla., distribution center's registration to distribute controlled substances; changes in the cost of commodities such as oil-based resins, cotton, latex and diesel fuel; and, with respect to future dividends, the decision by the Cardinal Health board of directors to declare such dividends, which decision will depend on Cardinal Health's surplus, earnings, cash flows, financial condition and prospects at the time any such action is considered. Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports. This news release reflects management's views as of May 3, 2012. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement.  Schedule 1CARDINAL HEALTH, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF EARNINGS (UNAUDITED)Third Quarter(in millions, except per Common Share amounts)20122011% ChangeRevenue$ 26,917.5$ 26,071.43 %Cost of products sold25,710.824,909.23 %Gross margin1,206.71,162.24 %Operating expenses:Distribution, selling, general and administrative expenses682.7669.52 %Restructuring and employee severance7.16.2N.M.Acquisition-related costs(26.6)30.3N.M.Impairments and loss on disposal of assets17.14.6N.M.Litigation (recoveries)/charges, net(0.2)4.3N.M.Operating earnings526.6447.318 %Other income, net(7.7)(6.2)24 %Interest expense, net23.925.1(5)%Loss on sale of investment in CareFusion-3.3N.M.Earnings before income taxes and discontinued operations510.4425.120 %Provision for income taxes177.9175.61 %Earnings from continuing operations332.5249.533 %Earnings/(loss) from discontinued operations, net of tax0.9(3.5)N.M.Net earnings$
    333.4$
    246.036 %Basic earnings/(loss) per Common Share:Continuing operations$
    .96$
    .7233 %Discontinued operations-(0.01)N.M.Net basic earnings per Common Share$
    .96$
    .7135 %Diluted earnings/(loss) per Common Share:Continuing operations$
    .95$
    .7134 %Discontinued operations-(0.01)N.M.Net diluted earnings per Common Share$
    .95$
    .7036 %Weighted average number of Common Shares outstanding:Basic345.3348.5Diluted349.5352.9Schedule 2CARDINAL HEALTH, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF EARNINGS (UNAUDITED)Year-to-Date(in millions, except per Common Share amounts)20122011% ChangeRevenue$ 80,787.5$ 75,880.76 %Cost of products sold77,382.572,762.06 %Gross margin3,405.03,118.79 %Operating expenses:Distribution, selling, general and administrative expenses1,965.61,857.76 %Restructuring and employee severance12.210.6N.M.Acquisition-related costs22.875.2N.M.Impairments and loss on disposal of assets19.48.2N.M.Litigation (recoveries)/charges, net(3.2)11.9N.M.Operating earnings1,388.21,155.120 %Other income, net(3.0)(19.4)N.M.Interest expense, net70.269.02 %Gain on sale of investment in CareFusion-(71.5)N.M.Earnings before income taxes and discontinued operations1,321.01,177.012 %Provision for income taxes487.1418.216 %Earnings from continuing operations833.9758.810 %Loss from discontinued operations, net of tax(1.7)(2.5)N.M.Net earnings$
    832.2$
    756.310 %Basic earnings/(loss) per Common Share:Continuing operations$
    2.42$
    2.1811 %Discontinued operations(0.01)(0.01)N.M.Net basic earnings per Common Share$
    2.41$
    2.1711 %Diluted earnings/(loss) per Common Share:Continuing operations$
    2.39$
    2.1611 %Discontinued operations(0.01)(0.01)N.M.Net diluted earnings per Common Share$
    2.38$
    2.1511 %Weighted average number of Common Shares outstanding:Basic345.0348.3Diluted349.2351.8Schedule 3CARDINAL HEALTH, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETSMarch 31,June 30,(in millions)20122011(UNAUDITED)AssetsCash and equivalents$
    2,410.4$
    ,929.3Trade receivables, net6,495.46,155.7Inventories8,220.17,334.2Prepaid expenses and other944.3896.7Total current assets18,070.216,315.9Property and equipment, net1,517.41,512.2Goodwill and other intangibles, net4,370.84,259.0Other assets683.7758.8Total assets$
    24,642.1$  22,845.9Liabilities and Shareholders' EquityAccounts payable$
    2,572.5$  11,331.5Current portion of long-term obligations and other short-term borrowings345.5326.7Other accrued liabilities1,928.11,711.3Total current liabilities14,846.113,369.5Long-term obligations, less current portion2,207.92,175.3Deferred income taxes and other liabilities1,348.01,452.5Total shareholders' equity6,240.15,848.6Total liabilities and shareholders' equity$
    24,642.1$  22,845.9Schedule 4CARDINAL HEALTH, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)Third QuarterYear-to-Date(in millions)2012201120122011CASH FLOWS FROM OPERATING ACTIVITIES:Net earnings$
    333.4$
    246.0$
    832.2$
    756.3(Earnings)/loss from discontinued operations(0.9)3.51.72.5Earnings from continuing operations332.5249.5833.9758.8Adjustments to reconcile earnings from continuing operations to net cash from operations:Depreciation and amortization83.597.5239.3239.2(Gain)/loss on sale of investment in CareFusion-3.3-(71.5)Impairments and loss on disposal of assets17.14.619.48.2Share-based compensation21.618.063.160.4Provision for bad debts5.014.46.722.2Change in fair value of contingent consideration obligation(53.2)(3.6)(53.2)(0.4)Change in operating assets and liabilities, net of effects from acquisitions:Increase in trade receivables(477.6)(470.3)(310.5)(578.9)Decrease/(increase) in inventories682.7552.2(869.9)(1,048.1)Increase in accounts payable94.6223.51,212.21,986.4Other accrued liabilities and operating items, net187.0225.0141.9(101.0)Net cash provided by operating activities-continuing operations893.2914.11,282.91,275.3Net cash used in operating activities-discontinued operations-(0.2)-(0.5)Net cash provided by operating activities893.2913.91,282.91,274.8CASH FLOWS FROM INVESTING ACTIVITIES:Acquisition of subsidiaries, net of cash acquired(135.3)-(142.6)(2,295.0)Purchase of held-to-maturity securities and other investments-(14.6)(10.5)(155.6)Additions to property and equipment(57.7)(59.8)(159.0)(183.1)Proceeds from sale of CareFusion---705.9Proceeds from maturities of held-to-maturity securities11.0-46.0-Net cash used in investing activities(182.0)(74.4)(266.1)(1,927.8)CASH FLOWS FROM FINANCING ACTIVITIES:Net change in short-term borrowings4.143.08.241.5Reduction of long-term obligations(43.5)(220.1)(44.5)(228.1)Proceeds from long-term obligations, net of issuance costs---494.5Proceeds from issuance of Common Shares11.925.122.936.0Tax proceeds/(disbursements) from exercises of stock options3.3(5.8)3.6(8.7)Dividends on Common Shares(74.3)(67.9)(225.9)(205.9)Purchase of treasury shares--(300.0)(269.8)Net cash used in financing activities(98.5)(225.7)(535.7)(140.5)Net increase/(decrease) in cash and equivalents612.7613.8481.1(793.5)Cash and equivalents at beginning of period1,797.71,348.01,929.32,755.3Cash and equivalents at end of period$ 2,410.4$ 1,961.8$ 2,410.4$
    ,961.8Schedule 5CARDINAL HEALTH, INC. AND SUBSIDIARIESTOTAL COMPANY BUSINESS ANALYSISNon-GAAPThird QuarterThird Quarter(in millions)2012201120122011RevenueAmount$ 26,918$ 26,071Growth Rate3 %7 %Operating EarningsAmount$
    527$
    447$
    524$
    493Growth Rate18 %22 %6 %27 %Earnings from Continuing OperationsAmount$
    332$
    250$
    327$
    286Growth Rate33 %11 %14 %28 %Non-GAAPYear-to-DateYear-to-Date(in millions)2012201120122011RevenueAmount$ 80,788$ 75,881Growth Rate6 %2 %Operating EarningsAmount$   1,388$   1,155$ 1,441$
    ,268Growth Rate20 %19 %14 %18 %Earnings from Continuing OperationsAmount$
    834$
    759$
    864$
    774Growth Rate10 %93 %12 %23 %Refer to the GAAP/Non-GAAP reconciliation for definitions and calculations supporting the Non-GAAP balances.Schedule 6CARDINAL HEALTH, INC. AND SUBSIDIARIESSEGMENT BUSINESS ANALYSISThird QuarterThird Quarter(in millions)20122011(in millions)20122011PHARMACEUTICALMEDICALRevenueRevenueAmount$
    24,508$
    23,845Amount$
    2,414$
    2,231Growth Rate3 %7 %Growth Rate8 %5 %Mix91 %91 %Mix9 %9 %Segment ProfitSegment ProfitAmount$
    446$
    411Amount$
    89$
    8Growth Rate9 %33 %Growth Rate(17)%0 %Mix83 %79 %Mix17 %21 %Segment Profit Margin1.82 %1.73 %Segment Profit Margin3.70 %4.84 %Refer to definitions for an explanation of calculations.Total consolidated revenue for the three months ended March 31, 2012 was $26,918 million, which included total segment revenue of $26,922 million and Corporate revenue of $(4) million. Total consolidated revenue for the three months ended March 31, 2011 was $26,071 million, which included total segment revenue of $26,076 million and Corporate revenue of $(5) million.  Corporate revenue consists primarily of elimination of inter-segment revenue.Total consolidated operating earnings for the three months ended March 31, 2012 were $527 million, which included total segment profit of $535 million and Corporate costs of $(8) million. Total consolidated operating earnings for the three months ended March 31, 2011 were $447 million, which included total segment profit of $519 million and Corporate costs of $(72) million. Corporate includes, among other things, restructuring and employee severance, acquisition-related costs (including amortization of acquisition-related intangible assets and changes in the fair value of contingent consideration obligations), impairments and loss on disposal of assets, litigation (recoveries)/charges, net and certain investment spending that are not allocated to the segments. Schedule 7CARDINAL HEALTH, INC. AND SUBSIDIARIESSEGMENT BUSINESS ANALYSISYear-to-DateYear-to-Date(in millions)20122011(in millions)20122011PHARMACEUTICALMEDICALRevenueRevenueAmount$ 73,591$ 69,286Amount$ 7,210$
    ,610Growth Rate6 %3 %Growth Rate9 %0 %Mix91 %91 %Mix9 %9 %Segment ProfitSegment ProfitAmount$   1,204$   1,021Amount$
    253$
    294Growth Rate18 %31 %Growth Rate(14)%(10)%Mix83 %78 %Mix17 %22 %Segment Profit Margin1.64 %1.47 %Segment Profit Margin3.51 %4.46 %Refer to definitions for an explanation of calculations.Total consolidated revenue for the nine months ended March 31, 2012 was $80,788 million, which included total segment revenue of $80,801 million and Corporate revenue of $(13) million. Total consolidated revenue for the nine months ended March 31, 2011 was $75,881 million, which included total segment revenue of $75,896 million and Corporate revenue of $(15) million. Corporate revenue consists primarily of elimination of inter-segment revenue.Total consolidated operating earnings for the nine months ended March 31, 2012 were $1,388 million, which included total segment profit of $1,457 million and Corporate costs of $(69) million. Total consolidated operating earnings for the nine months ended March 31, 2011 were $1,155 million, which included total segment profit of $1,315 million and Corporate costs of $(160) million. Corporate includes, among other things, restructuring and employee severance, acquisition-related costs (including amortization of acquisition-related intangible assets and changes in the fair value of contingent consideration obligations), impairments and loss on disposal of assets, litigation (recoveries)/charges, net and certain investment spending that are not allocated to the segments.Schedule 8CARDINAL HEALTH, INC. AND SUBSIDIARIESSCHEDULE OF NOTABLE ITEMSThird QuarterYear-to-Date(in millions, except per Common Share amounts)2012201120122011Restructuring and Employee SeveranceRestructuring and employee severance$   (7.1)$   (6.2)$ (12.2)$
    (10.6)Tax benefit2.72.44.64.1Restructuring and employee severance, net of tax$   (4.4)$   (3.8)$   (7.6)$
    (6.5)Decrease to diluted EPS from continuing operations$ (0.01)$ (0.01)$ (0.02)$
    (0.02)Acquisition-Related CostsAmortization of acquisition-related intangible assets$ (20.4)$ (27.9)$ (57.9)$
    (53.4)Tax benefit7.27.420.713.2Amortization of acquisition-related intangible assets, net of tax$ (13.2)$ (20.5)$ (37.2)$
    (40.2)Decrease to diluted EPS from continuing operations$ (0.04)$ (0.06)$ (0.11)$
    (0.11)Other acquisition-related costs (1)$  47.0$   (2.5)$  35.2$
    (21.8)Tax benefit/(expense) (1)(13.5)0.4(9.9)2.4Other acquisition-related costs, net of tax$  33.5$   (2.1)$  25.3$
    (19.4)Increase/(decrease) to diluted EPS from continuing operations (1)$  0.10$ (0.01)$  0.07$
    (0.06)Total acquisition-related costs (2)$  26.6$ (30.3)$ (22.8)$
    (75.2)Tax benefit/(expense) (2)(6.4)7.810.815.6Total acquisition-related costs, net of tax (2)$  20.2$ (22.5)$ (12.0)$
    (59.6)Increase/(decrease) to diluted EPS from continuing operations (2)$  0.06$ (0.06)$ (0.03)$
    (0.17)Impairments and Loss on Disposal of AssetsImpairments and loss on disposal of assets$ (17.1)$   (4.6)$ (19.4)$
    (8.2)Tax benefit6.71.87.63.1Impairments and loss on disposal of assets, net of tax$ (10.4)$   (2.8)$ (11.8)$
    (5.1)Decrease to diluted EPS from continuing operations$ (0.03)$ (0.01)$ (0.03)$
    (0.01)Litigation Recoveries/(Charges), NetLitigation recoveries/(charges), net$
    .2$   (4.3)$
    3.2$
    (11.9)Tax benefit/(expense)(0.1)0.4(1.2)1.4Litigation recoveries/(charges), net, net of tax$
    .1$   (3.9)$
    2.0$
    (10.5)Increase/(decrease) to diluted EPS from continuing operations$
    -$ (0.01)$  0.01$
    (0.03)Other Spin-Off CostsOther spin-off costs$   (0.2)$   (0.7)$   (1.5)$
    (7.4)Tax benefit0.10.30.62.8Other spin-off costs, net of tax$   (0.1)$   (0.4)$   (0.9)$
    (4.6)Decrease to diluted EPS from continuing operations$
    -$
    -$
    -$
    (0.01)(Gain)/Loss on Sale of CareFusion Stock(Gain)/loss on sale of CareFusion stock$
    -$   (3.3)$
    -$
    71.5Tax benefit----(Gain)/loss on sale of CareFusion stock, net of tax$
    -$   (3.3)$
    -$
    71.5Increase/(decrease) to diluted EPS from continuing operations$
    -$ (0.01)$
    -$
    .20Weighted Average Number of Diluted Shares Outstanding349.5352.9349.2351.8We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.(1) Includes a $54.7 million decrease in the fair value of the total contingent consideration obligation related to the P4 Healthcare acquisition for the three months ended March 31, 2012. The related tax expense was $20.1 million and diluted EPS from continuing operations increased $0.10.(2) The sum of the components may not equal the total due to rounding.Schedule 9CARDINAL HEALTH, INC. AND SUBSIDIARIESASSET MANAGEMENT ANALYSISThird QuarterYear-to-Date2012201120122011Days Sales Outstanding21.219.7Days Inventory on Hand25.024.5Days Payable Outstanding38.338.0Net Working Capital Days7.96.2Debt to Total Capital29 %30 %Net Debt to Capital2 %8 %Return on Equity21.9 %17.8 %18.7 %18.7 %Non-GAAP Return on Equity21.6 %20.7 %19.4 %19.1 %Effective Tax Rate from Continuing Operations34.9 %41.3 %36.9 %35.5 %Non-GAAP Effective Tax Rate from Continuing Operations35.6 %39.7 %37.1 %36.5 %Refer to the GAAP/Non-GAAP reconciliation for Non-GAAP calculations. Refer to DSO, DIOH and DPO for definitions and calculations.Schedule 10

    CARDINAL HEALTH, INC. AND SUBSIDIARIES
    GAAP / NON-GAAP RECONCILIATIONS

    (in millions, except per Common Share amounts)Third Quarter 2012EarningsBeforeEarningsDilutedIncomeProvisionEarningsfromDilutedEPS fromOperatingTaxes andforfromContinuingEPS fromContinuingOperatingEarningsDiscontinuedIncomeContinuingOperationsContinuingOperationsEarningsGrowth RateOperationsTaxes(1)OperationsGrowth RateOperationsGrowth RateGAAP$
    52718 %$
    510$
    78$
    33233 %$
    .9534 %Restructuring and Employee Severance77

    3

    40.01Acquisition-Related Costs(27)(27)

    (6)

    (20)(0.06)Impairments and Loss on Disposal of Assets1717

    7

    100.03Litigation (Recoveries)/Charges, net--

    -

    --Other Spin-Off Costs--

    -

    --Loss on Sale of CareFusion Stock--

    -

    --Non-GAAP$
    5246 %$
    508$
    81$
    32714 %$
    .9416 %Third Quarter 2011EarningsBeforeEarningsDilutedIncomeProvisionEarningsfromDilutedEPS fromOperatingTaxes andforfromContinuingEPS fromContinuingOperatingEarningsDiscontinuedIncomeContinuingOperationsContinuingOperationsEarningsGrowth RateOperationsTaxes(1)OperationsGrowth RateOperationsGrowth RateGAAP$
    44722 %$
    425$
    76$
    25011 %$
    .7115 %Restructuring and Employee Severance66

    2

    40.01Acquisition-Related Costs3030

    8

    230.06Impairments and Loss on Disposal of Assets55

    2

    30.01Litigation (Recoveries)/Charges, net44

    -

    40.01Other Spin-Off Costs11

    -

    --Loss on Sale of CareFusion Stock-3

    -

    30.01Non-GAAP$
    49327 %$
    475$
    88$
    28628 %$
    .8131 %Year-to-Date 2012EarningsBeforeEarningsDilutedIncomeProvisionEarningsfromDilutedEPS fromOperatingTaxes andforfromContinuingEPS fromContinuingOperatingEarningsDiscontinuedIncomeContinuingOperationsContinuingOperationsEarningsGrowth RateOperationsTaxes(1)OperationsGrowth RateOperationsGrowth RateGAAP$
    ,38820 %$
    ,321$
    487$
    83410 %$
    2.3911 %Restructuring and Employee Severance1212

    5

    80.02Acquisition-Related Costs2323

    11

    120.03Impairments and Loss on Disposal of Assets1919

    8

    120.03Litigation (Recoveries)/Charges, net(3)(3)

    (1)

    (2)(0.01)Other Spin-Off Costs22

    1

    1-Gain on Sale of CareFusion Stock--

    -

    --Non-GAAP$
    ,44114 %$
    ,374$
    509$
    86412 %$
    2.4712 %Year-to-Date 2011EarningsBeforeEarningsDilutedIncomeProvisionEarningsfromDilutedEPS fromOperatingTaxes andforfromContinuingEPS fromContinuingOperatingEarningsDiscontinuedIncomeContinuingOperationsContinuingOperationsEarningsGrowth RateOperationsTaxes(1)OperationsGrowth RateOperationsGrowth RateGAAP$
    ,15519 %$
    ,177$
    418$
    75993 %$
    2.1698 %Restructuring and Employee Severance1111

    4

    70.02Acquisition-Related Costs7575

    16

    600.17Impairments and Loss on Disposal of Assets88

    3

    50.01Litigation (Recoveries)/Charges, net1212

    1

    110.03Other Spin-Off Costs77

    3

    50.01Gain on Sale of CareFusion Stock-(72)

    -

    (72)(0.20)Non-GAAP$
    ,26818 %$
    ,219$
    445$
    77423 %$
    2.2026 %The sum of the components may not equal the total due to rounding.(1)

    We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.Schedule 11CARDINAL HEALTH, INC. AND SUBSIDIARIESGAAP / NON-GAAP RECONCILIATIONThird Quarter(in millions)20122011GAAP Return on Equity21.9 %17.8 %Non-GAAP Return on EquityNet earnings$
    333.4$
    246.0Restructuring and employee severance, net of tax, in continuing operations(1)4.43.8Acquisition-related costs, net of tax, in continuing operations(1)(20.2)22.5Impairments and loss on disposal of assets, net of tax, in continuing operations(1)10.42.8Litigation (recoveries)/charges, net, net of tax, in continuing operations(1)(0.1)3.9Other spin-off costs, net of tax, in continuing operations(1)0.10.4Loss on sale of CareFusion stock, net of tax(1)-3.3CareFusion net loss in discontinued operations(1,2)-3.3Adjusted net earnings$
    328.0$
    286.0Annualized$ 1,312.0$ 1,144.0ThirdSecondThirdSecondQuarterQuarterQuarterQuarter2012201220112011Total shareholders' equity$ 6,240.1$ 5,927.7$ 5,656.8$
    5,421.4Divided by average shareholders' equity$ 6,083.9$ 5,539.1Non-GAAP Return on Equity21.6 %20.7 %(1)

    We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.(2)

    To properly reflect the impact of the spin-off, on a non-GAAP basis, CareFusion net earnings included in discontinued operations are excluded from adjusted net earnings for all periods presented.
    Schedule 12CARDINAL HEALTH, INC. AND SUBSIDIARIESGAAP / NON-GAAP RECONCILIATIONYear-to-DateYear-to-Date(in millions)20122011GAAP Return on Equity18.7 %18.7 %Non-GAAP Return on EquityNet earnings$
    832.2$
    756.3Restructuring and employee severance, net of tax, in continuing operations (1)7.66.5Acquisition-related costs, net of tax, in continuing operations (1)12.059.6Impairments and loss on disposal of assets, net of tax, in continuing operations (1)11.85.1Litigation (recoveries)/charges, net, net of tax, in continuing operations (1)(2.0)10.5Other spin-off costs, net of tax, in continuing operations (1)0.94.6Gain on sale of CareFusion stock, net of tax (1)-(71.5)CareFusion net loss in discontinued operations (1,2)-3.3Adjusted net earnings$
    862.5$
    774.4Annualized$
    ,150.0$
    ,032.5ThirdSecondFirstFourthThirdSecondFirstFourthQuarterQuarterQuarterQuarterQuarterQuarterQuarterQuarter20122012201220112011201120112010Total shareholders' equity$
    ,240.1$ 5,927.7$ 5,713.9$ 5,848.6$
    5,656.8$ 5,421.4$ 5,239.0$
    5,276.1Divided by average shareholders' equity$
    5,932.6$
    5,398.3Non-GAAP Return on Equity19.4 %19.1 %(1)

    We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.(2)

    To properly reflect the impact of the spin-off, on a non-GAAP basis, CareFusion net earnings included in discontinued operations are excluded from adjusted net earnings for all periods presented.
    Schedule 13CARDINAL HEALTH, INC. AND SUBSIDIARIESGAAP / NON-GAAP RECONCILIATIONThird QuarterYear-to-Date(in millions)2012201120122011GAAP Effective Tax Rate from Continuing Operations34.9 %41.3 %36.9 %35.5 %Non-GAAP Effective Tax Rate from Continuing OperationsEarnings before income taxes and discontinued operations$
    510.4$
    425.1$ 1,321.0$
    ,177.0Restructuring and employee severance7.16.212.210.6Acquisition-related costs(26.6)30.322.875.2Impairments and loss on disposal of assets17.14.619.48.2Litigation (recoveries)/charges, net(0.2)4.3(3.2)11.9Other spin-off costs0.20.71.57.4(Gain)/loss on sale of CareFusion stock-3.3-(71.5)Adjusted earnings before income taxes and discontinued operations$
    508.0$
    474.5$ 1,373.7$
    ,218.8Provision for income taxes (1)$
    77.9$
    75.6$
    487.1$
    418.2Restructuring and employee severance tax benefit (1)2.72.44.64.1Acquisition-related costs tax benefit/(expense) (1)(6.4)7.810.815.6Impairments and loss on disposal of assets tax benefit (1)6.71.87.63.1Litigation (recoveries)/charges, net tax benefit/(expense) (1)(0.1)0.4(1.2)1.4Other spin-off costs tax benefit (1)0.10.30.62.8(Gain)/loss on sale of CareFusion stock tax benefit (1)----Adjusted provision for income taxes$
    80.9$
    88.3$
    509.5$
    445.2Non-GAAP Effective Tax Rate from Continuing Operations35.6 %39.7 %37.1 %36.5 %Third Quarter20122011Debt to Total Capital29 %30 %Net Debt to CapitalCurrent portion of long-term obligations and other short-term borrowings$
    345.5$
    3.7Long-term obligations, less current portion2,207.92,362.1Debt$ 2,553.4$ 2,475.8Cash and equivalents(2,410.4)(1,961.8)Net Debt$
    43.0$
    514.0Total shareholders' equity6,240.15,656.8Capital$ 6,383.1$ 6,170.8Net Debt to Capital2 %8 %(1)

    We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.Forward-Looking Non-GAAP Financial Measures We present non-GAAP earnings from continuing operations and non-GAAP effective tax rate from continuing operations (and presentations derived from these financial measures, including per share calculations) on a forward-looking basis. The most directly comparable forward-looking GAAP measures are earnings from continuing operations and effective tax rate from continuing operations. We are unable to provide a quantitative reconciliation of these forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measures because we cannot reliably forecast restructuring and employee severance, acquisition-related costs (including amortization of acquisition-related intangible assets and changes in the fair value of contingent consideration obligations), impairments and loss on disposal of assets, litigation (recoveries)/charges, net, and other spin-off costs, which are difficult to predict and estimate and are primarily dependent on future events. Please note that the unavailable reconciling items could significantly impact our future financial results.
    Schedule 14CARDINAL HEALTH, INC. AND SUBSIDIARIESThird Quarter(in millions)20122011Days Sales Outstanding21.219.7Days Inventory on HandInventories$   8,220.1$
    7,717.7Cost of products sold$ 25,710.8$
    24,909.2Chargeback billings3,842.53,453.4Adjusted cost of products sold$ 29,553.3$
    28,362.6Adjusted cost of products sold divided by 90 days$
    328.4$
    315.1Days Inventory on Hand25.024.5Days Payable OutstandingAccounts payable$ 12,572.5$
    ,961.5Cost of products sold$ 25,710.8$
    24,909.2Chargeback billings3,842.53,453.4Adjusted cost of products sold$ 29,553.3$
    28,362.6Adjusted cost of products sold divided by 90 days$
    328.4$
    315.1Days Payable Outstanding38.338.0Net Working Capital Days7.96.2Days Sales Outstanding:
    trade receivables, net divided by (monthly revenue divided by 30 days).Days Inventory on Hand:
    inventory divided by ((quarterly cost of products sold plus chargeback billings) divided by 90 days). Chargeback billings are the difference between a product's wholesale acquisition cost and the contract price established between pharmaceutical manufacturers and the end customer.Days Payable Outstanding: accounts payable divided by ((quarterly cost of products sold plus chargeback billings) divided by 90 days). Chargeback billings are the difference between a product's wholesale acquisition cost and the contract price established between pharmaceutical manufacturers and the end customer.Net Working Capital Days: days sales outstanding plus days inventory on hand less days payable outstanding.CARDINAL HEALTH, INC. AND SUBSIDIARIESUse of Non-GAAP MeasuresThis earnings release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP").  In general, the measures exclude items and charges that (i) management does not believe reflect Cardinal Health, Inc.'s (the "Company") core business and relate more to strategic, multi-year corporate activities; or (ii) relate to activities or actions that may have occurred over multiple or in prior periods without predictable trends.  Management uses these non-GAAP financial measures internally to evaluate the Company's performance, evaluate the balance sheet, engage in financial and operational planning and determine incentive compensation.Management provides these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on its financial and operating results and in comparing the Company's performance to that of its competitors.  However, the non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.The non-GAAP financial measures disclosed by the Company should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth above should be carefully evaluated.DefinitionsDebt: long-term obligations plus short-term borrowings.Debt to Total Capital: debt divided by (debt plus total shareholders' equity).Net Debt: a Non-GAAP measure defined as debt minus (cash and equivalents).Net Debt to Capital: a Non-GAAP measure defined as net debt divided by (net debt plus total shareholders' equity).Non-GAAP Diluted EPS from Continuing Operations and growth rate calculation (1): non-GAAP earnings from continuing operations divided by diluted weighted average shares outstanding. Non-GAAP Earnings from Continuing Operations and growth rate calculation: earnings from continuing operations excluding (1) restructuring and employee severance (2), (2) acquisition-related costs (3), (3) impairments and loss on disposal of assets (4), (4) litigation (recoveries)/charges, net (5), (5) Other Spin-Off Costs and (6) (gain)/loss on sale of CareFusion stock, each net of tax. Non-GAAP Effective Tax Rate from Continuing Operations: (provision for income taxes adjusted for (1) restructuring and employee severance, (2) acquisition-related costs, (3) impairments and loss on disposal of assets, (4) litigation (recoveries)/charges, net, (5) Other Spin-Off Costs and (6) (gain)/loss on sale of CareFusion stock) divided by (earnings before income taxes and discontinued operations adjusted for the same six items). Non-GAAP Operating Earnings and growth rate calculation: operating earnings excluding (1) restructuring and employee severance, (2) acquisition-related costs, (3) impairments and loss on disposal of assets, (4) litigation (recoveries)/charges, net and (5) Other Spin-Off Costs.Non-GAAP Return on Equity: (annualized current period net earnings excluding (1) restructuring and employee severance, (2) acquisition-related costs, (3) impairments and loss on disposal of assets, (4) litigation (recoveries)/charges, net, (5) Other Spin-Off Costs, (6) (gain)/loss on sale of CareFusion stock and (7) CareFusion net earnings in discontinued operations, each net of tax) and divided by average shareholders' equity.Other Spin-Off Costs: costs incurred in connection with our Spin-Off of CareFusion which are included in distribution, selling, general and administrative expenses. Return on Equity: annualized current period net earnings divided by average shareholders' equity. Revenue Mix: segment revenue divided by total segment revenue for all segments. Segment Profit: segment revenue minus (segment cost of products sold and segment distribution, selling, general and administrative expenses). Segment Profit Margin: segment profit divided by segment revenue. Segment Profit Mix: segment profit divided by total segment profit for all segments.(1)

    In this earnings release growth rates are determined by dividing the difference between current period results and prior period results by prior period results.(2)

    Programs whereby the Company fundamentally changes its operations such as closing and consolidating certain manufacturing and distribution facilities, moving manufacturing of a product to another location, outsourcing the production of a product, employee severance (including rationalizing headcount or other significant changes in personnel) and realigning operations (including substantial realignment of the management structure of a business unit in response to changing market conditions).(3)

    Costs that consist primarily of transaction costs, integration costs, changes in the fair value of contingent consideration obligations and amortization of acquisition-related intangible assets.(4)

    Asset impairments and losses from the disposal of assets not eligible to be classified as discontinued operations are classified within impairments and loss on disposal of assets within the consolidated statements of earnings.(5)

    Loss contingencies related to litigation and regulatory matters and income from favorable resolution of legal matters.


    '/>"/>

    SOURCE Cardinal Health, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
    2. Stem Cell Breakthrough Advances Science Without Ethical Landmines, Says Cardinal
    3. Hydrox Inc., Cardinal Health Issue Nationwide Recall of Alcohol-Free Mouthwash For Hospitals
    4. Cardinal Health Completes Enturia Acquisition
    5. Cardinal Health Expands PET Nuclear Pharmacy Services to Support Clinical Drug Trials
    6. AmeriCares Honors Cardinal Health with Power of Partnership Award
    7. Cardinal Health Helps Hospitals Save More Than $20 Million In Pharmaceutical Costs; Connect Low-Income Patients With Affordable Medications
    8. Cardinal Health Executives to Speak at Two Investor Events in January
    9. Cardinal Health Names Carrie Cox to Board of Directors
    10. Cardinal Health Raises Quarterly Dividend By 11 Percent
    11. Cardinal Health Supports ACRIN Clinical Trials Evaluating Oncologic Biotracers
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/12/2016)... 2016 On Thursday, Feb. 11, 2016, surgeons ... David,s North Austin Medical Center successfully completed the first ... ® Surgical System with Trumpf Medical,s advanced operating ... Lakshman , M.D., colorectal surgeon at the Texas Institute ... Table Motion technology, which seamlessly combines the da Vinci ...
    (Date:2/12/2016)... Ga. , Feb. 12 2016  OMS Supply, ... dental and medical practitioners, announced today the recent launching ... offers visitors a variety of features that enhance the ... oral surgery supplies. --> ... is a fairly new company that started in early ...
    (Date:2/12/2016)... Maharashtra, February 12, 2016 ... report titled Chronic Inflammation Global Clinical Trials Review, ... of the global clinical trials landscape along with ... by Region, Country (G7 & E7), Trial Status, ... and reviews top companies involved and enlists all ...
    Breaking Medicine Technology:
    (Date:2/13/2016)... ... February 13, 2016 , ... With FCPX Overlay Embers from ... all within Final Cut Pro X. Each user can select from up to 40 ... of view, blur, focus offset, hue, saturation, value, contrast, glow, and more all within ...
    (Date:2/13/2016)... Tennessee (PRWEB) , ... February 13, 2016 , ... ... Herrington School of Nursing with an in-kind gift of a VeinViewer® Vision ... students as they learn how to start an IV and draw blood, combining ...
    (Date:2/13/2016)... ... February 13, 2016 , ... DDi , ... Solution Providers list for its expertise in eClinical Solutions. DDi has built its ... the technology needs of global clients. DDi provides smarter technology for Clinical Development, ...
    (Date:2/12/2016)... LA (PRWEB) , ... February 12, 2016 , ... The ... St. Landry and Evangeline Parishes. The purpose of these scholarships is to encourage ... encourage those individuals to seek employment within these two parishes. , “We have ...
    (Date:2/12/2016)... ... ... , Back to the Future , Feb. 25, 2016 — 11:00 a.m. – 12:30 p.m. ... learn from history are doomed to repeat it.” , An analysis of CDRH’s enforcement actions ... takes time. , Take a close look at the warning letters the agency sent ...
    Breaking Medicine News(10 mins):